HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials

Journal Article

2012

Permanent link to this Item
http://hdl.handle.net/11427/15226
 http://dx.doi.org/10.1186/1742-4690-9-S2-P131
Files
Volk_HIV_vaccine_trial_safety_2012.pdf (129.37 KB)
Authors
Volk, JE
Hessol, NA
Gray, GE
Kublin, JG
Churchyard, G
Mlisana, K
Nchabeleng, M
Buchbinder, SP
Bekker, L
Journal Title

Retrovirology

Link to Journal
http://www.retrovirology.com/
Journal ISSN
Volume Title
Publisher

BioMed Central Ltd

Publisher

University of Cape Town

Department
Desmond Tutu HIV Centre
Faculty
Faculty of Health Sciences
License

http://creativecommons.org/licenses/by/2.0

Series
Abstract
Worldwide, many adolescents, especially women, acquire HIV before age 18. Yet to date, no HIV vaccine trials have enrolled adolescents. Reasons for excluding adolescents from these trials include regulations protecting vulnerable subjects and concerns regarding informed consent, social harms, adverse events, and loss to follow-up.
Description
Keywords
HIV vaccine trials
adolescents
vulnerable subjects

Reference:

Volk, J. E., Hessol, N. A., Gray, G. E., Kublin, J. G., Churchyard, G., Mlisana, K., ... & Bekker, L. (2012). HIV vaccine trial safety and retention among 18-20 year olds in the HVTN 503/Phambili study support the inclusion of adolescents in future trials. Retrovirology, 9(Suppl 2), P131.

Collections
Journal Articles